H-LEU-SER-LYS-LEU-OH
H-LEU-SER-LYS-LEU-OH Basic information
- Product Name:
- H-LEU-SER-LYS-LEU-OH
- Synonyms:
-
- LEU-SER-LYS-LEU
- H-LEU-SER-LYS-LEU-OH
- L-Leucine, L-leucyl-L-seryl-L-lysyl-
- L-Leucyl-L-seryl-L-lysyl-L-leucine
- Inhibitor of Thrombospondin (TSP-1) (TFA)
- CAS:
- 162559-45-7
- MF:
- C21H41N5O6
- MW:
- 459.58
- Product Categories:
-
- TGF-βKinase/Phosphatase Biology
- Tyrosine Kinase-Like Substrates
- Cytokines and Growth Factors
- Transforming Growth Factor-β (TGF-β) and Superfamily
- Tyrosine Kinase-Like Biology
- Mol File:
- 162559-45-7.mol
H-LEU-SER-LYS-LEU-OH Chemical Properties
- Boiling point:
- 803.2±65.0 °C(Predicted)
- Density
- 1.164±0.06 g/cm3(Predicted)
- storage temp.
- −20°C
- pka
- 3.37±0.10(Predicted)
MSDS
- Language:English Provider:SigmaAldrich
H-LEU-SER-LYS-LEU-OH Usage And Synthesis
Uses
H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK.html" class="link-product" target="_blank">KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis[1].
in vivo
H-Leu-Ser-Lys-Leu-OH (LSKL) (100 μg/0.5 mL; i.p.; daily for 4 weeks, accompanied with DMN) protects dimethylnitrosamine (DMN)-treated (10 mg/kg; i.p.; 3 consecutive days a week for 4 weeks) rats from liver atrophy. H-Leu-Ser-Lys-Leu-OH also prevents the progression of hepatic damage and fibrosis[1].
References
[1] Kondou H, et al. A blocking peptide for transforming growth factor-beta1 activation prevents hepatic fibrosis in vivo. J Hepatol. 2003 Nov;39(5):742-8. DOI:10.1016/s0168-8278(03)00377-5
H-LEU-SER-LYS-LEU-OHSupplier
- Tel
- 21-61263452 13641803416
- ymbetter@glbiochem.com
- Tel
- 021-54306202 13764082696
- info@hanhongsci.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 17705183659
- sales@njleonbiotech.com
- Tel
- 025-58361106-805 15951641583
- zhao.xu@njpeptide.com